Incidence of hepatitis C recurrence after kidney transplantation and response to direct-acting antiviral therapy

Aim: The purpose of this study is to investigate the efficacy and graft survival of direct antiviral agents in Hepatitis C-positive renal transplant recipients. Design: A Multi center study. Duration & place of study: From February 2020 to February 2021, a cohort of Hepatitis C positive Renal Transplant Recipients will participate in a study at the Saidu teachnig hospital  Swat and ikd peshawar. Methodology: the study conducted in STH and IKD peshawar  Patients with hepatitis C who have received a kidney transplant will be chosen if they meet the inclusion and exclusion criteria, and then they will be followed for three months after starting the direct acting antiviral (DAA) treatment. Result: With a mean age of 35.01±11.6 years, the study's 100 participants were evenly split between sexes (62% male). The treatment for HCV was a [100%] success. Throughout the course of therapy (ranging from 6-12 weeks), there was no discernible shift in the mean values of total bilirubin, haemoglobin, platelet count, serum creatinine, or estimated glomerular filtration rate. ALP levels decreased considerably across all time points of follow-up, whereas ALT and AST levels decreased rapidly over the first 4 weeks and thereafter stabilised. 